Where does Cancer Intelligence Care Systems, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cancer Intelligence Care Systems, Inc. ranks #39,308 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cancer Intelligence Care Systems, Inc. hold?

Cancer Intelligence Care Systems, Inc. holds 6 US utility patents granted between 2017 and 2021, spanning 11 technology areas.

What is Cancer Intelligence Care Systems, Inc.'s Innovation Score?

Cancer Intelligence Care Systems, Inc. has an Innovation Score of 25.4 out of 100 (17th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Cancer Intelligence Care Systems, Inc.'s patent grant rate increasing or decreasing?

Cancer Intelligence Care Systems, Inc.'s recent grant velocity is -50% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Cancer Intelligence Care Systems, Inc.'s patents?

Cancer Intelligence Care Systems, Inc.'s patents average 11.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cancer Intelligence Care Systems, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cancer Intelligence Care Systems, Inc.

Q: What technology areas does Cancer Intelligence Care Systems, Inc. focus on?

Cancer Intelligence Care Systems, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 4 patents. Grants appear in 11 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 11 technology areas, recorded in grant years 2017–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cancer ranks #39,308 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 11 technology areas.

#39,308
of 49,997 US assignees by volume: 17th percentile
by Innovation Score (25.4/100): 11.7
avg claims per patent: -50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R39308 · Foreign Corporation #39,308 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #39,308/49,997
PHOTO-FINISH Camoplast Solideal
CPC-FOCUS A61N · 11 areas
INNOV-THIN 25.4/100
CLAIMS-PAR 11.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Camoplast Solideal Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Cancer Intelligence… · this assignee

25
3D Lighting… · lowest

7

What this shows Cancer's Innovation Score is 25.4/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Cancer's grants concentrate

Cancer Intelligence Care Systems, Inc. is a focused PatentsView assignee: 11 CPC subclasses with 66.7% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2018. By volume, Cancer sits between Camoplast Solideal Inc. and Canyon Oak Energy LLC.

Camoplast Solideal

6
Camposol

6
Can-am Tool

6
Canary Capital

6
Cantel (UK)

6
Cantex Pharmaceut…

6
Canyon IP Holdings

6
Canyon Oak Energy

6
Cancer Intelligen… ◀

6

What this shows Cancer holds 6 patents at rank #39,493, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cancer

By rank, the assignees closest to #39,493 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Cancer's primary technology class.

Cancer's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 17th percentile higher than 17% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Cancer Intelligence Care Systems, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	2	33.3%
2018	1	16.7%
2019	1	16.7%
2020	1	16.7%
2021	1	16.7%

Which technologies does Cancer Intelligence Care Systems, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 4

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

Y02E - Reduction OF Greenhouse GAS [GHG] Emissions, Related TO Energy Generation, Transmission OR Distribution 2

C04B - Lime, MAGNESIA; SLAG; CEMENTS; Compositions Thereof, e.g. Mortars, Concrete OR Like Building MATERIALS; Artificial Stone ; Ceramics ; REFRACTORIES; Treatment OF Natural Stone 2

B32B - Layered Products, i.e. Products Built-up OF Strata OF Flat OR Non-flat, e.g. Cellular OR Honeycomb, Form 2

H05H - Plasma Technique ; Production OF Accelerated Electrically-charged Particles OR OF NEUTRONS; Production OR Acceleration OF Neutral Molecular OR Atomic Beams 2

C09K - Materials FOR Miscellaneous Applications, NOT Provided FOR Elsewhere 1

G01T - Measurement OF Nuclear OR X-radiation 1

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

G21K - Techniques FOR Handling Particles OR Ionising Radiation NOT Otherwise Provided FOR; Irradiation DEVICES; Gamma RAY OR X-ray Microscopes 1

C23C - Coating Metallic MATERIAL; Coating Material With Metallic MATERIAL; Surface Treatment OF Metallic Material BY Diffusion Into THE Surface, BY Chemical Conversion OR SUBSTITUTION; Coating BY Vacuum Evaporation, BY Sputtering, BY ION Implantation OR BY Chemical Vapour Deposition, IN General 1

Top 11 of 11 technology areas

Where it ranks

Overall rank by patents

#39,308

of 49,997 tracked assignees

Innovation Score

25.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Cancer Intelligence Care Systems, Inc.'s patent record in context - here's where to go next.

Cancer Intelligence Care Systems, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 66.7% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #39,308 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cancer Intelligence Care Systems, Inc. against Camoplast Solideal Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.